Bristol Myers Squibb’s oral CELMoD is the first cereblon modulator designed from the ground up for fast, deep protein degradation — and its positive Phase 3 SUCCESSOR-2 readout signals a new standard for relapsed/refractory multiple myeloma. 1. Why…
How a single small molecule can staple two proteins together and send one of them to the cellular shredder — the mechanism, the medicinal-chemistry logic, and a worked synthesis of the archetypal drug. 1. Why “glue” is the…
Field Value Target name Bromodomain-containing protein 4 (BRD4); BET family member (UniProt O60885) Gene BRD4 — chromosome 19p13.12; NCBI Gene 23476 Class Epigenetic ‘reader’. BET (Bromodomain & Extra-Terminal) family — two tandem bromodomains (BD1, BD2) plus an ET…
In the conventional ADC narrative, the antibody picks the cell, the payload kills it, and the linker just holds them together until they get there. The picture is wrong in roughly the same way that calling a fuel…
In the last five years, targeted protein degradation has gone from an academic curiosity to an industry-wide drug discovery priority. Roughly thirty PROTACs are in human clinical trials as of early 2026. Several are deep into Phase 2…